Drug intelligence / Profile preview

SLOG + FOLFIRINOX + GOFL

Development stage
Unknown
Lead developer
Taiwan Cooperative Oncology Group
Modality
Small Molecules
Administration
Intravenous
01

Overview

SLOG + FOLFIRINOX + GOFL appears to describe a multi-drug chemotherapy regimen composed of the drugs or regimens referred to as SLOG, FOLFIRINOX, and GOFL. - **FOLFIRINOX** is a well-documented combination chemotherapy regimen for advanced pancreatic cancer, consisting of four drugs: folinic acid (leucovorin), fluorouracil (5-FU), irinotecan, and oxaliplatin. It acts by inhibiting DNA synthesis and repair and topoisomerase-mediated DNA processes, thereby killing rapidly dividing tumor cells[1][2][3][5][6]. - The compose and mechanisms of SLOG and GOFL are not defined in the sources found. However, these similarly-structured acronym regimens are often used in oncology to refer to specific combinations of chemotherapy agents. In general, combination chemotherapy regimens such as this are used to increase efficacy against cancer by employing several drugs with different mechanisms of action.

02

Targets

TS (Thymidylate synthase)DHFR (Dihydrofolate reductase)

Beyond the preview

Go deeper on SLOG + FOLFIRINOX + GOFL.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on SLOG + FOLFIRINOX + GOFL.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call